| 1 |
35363275 | Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. | 2022 Jun 1 |
1 |
| 2 |
35524184 | Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. | 2022 May 6 |
1 |
| 3 |
33528846 | KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. | 2021 Apr |
2 |
| 4 |
33818022 | Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). | 2021 Apr |
4 |
| 5 |
33920789 | MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers. | 2021 Apr 15 |
2 |
| 6 |
34032767 | Long-term response on letrozole for gastric cancer: A case report. | 2021 May 28 |
1 |
| 7 |
34267813 | Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness. | 2021 Aug |
1 |
| 8 |
34356536 | Role of Persistent Organic Pollutants in Breast Cancer Progression and Identification of Estrogen Receptor Alpha Inhibitors Using In-Silico Mining and Drug-Drug Interaction Network Approaches. | 2021 Jul 19 |
1 |
| 9 |
31727690 | Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. | 2020 Feb |
1 |
| 10 |
32125937 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). | 2020 Apr 20 |
2 |
| 11 |
32151708 | Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. | 2020 Jun |
2 |
| 12 |
32683565 | Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). | 2020 Sep |
1 |
| 13 |
32713085 | Ribociclib therapy in peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer: A clinical case with a positive outcome. | 2020 Sep |
1 |
| 14 |
32988919 | Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. | 2020 Oct |
1 |
| 15 |
31092464 | The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. | 2019 May |
1 |
| 16 |
31217344 | Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. | 2019 Dec |
1 |
| 17 |
29157627 | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. | 2018 Jan |
1 |
| 18 |
29168427 | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). | 2018 Jan |
1 |
| 19 |
29337187 | Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. | 2018 Mar 15 |
2 |
| 20 |
29581135 | ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. | 2018 Jun 1 |
1 |
| 21 |
29733541 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. | 2018 Jun |
2 |
| 22 |
28163101 | Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. | 2017 Nov 15 |
3 |
| 23 |
28643023 | Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. | 2017 Oct |
4 |
| 24 |
28794284 | Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. | 2017 Aug 9 |
1 |
| 25 |
28842253 | Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells. | 2017 Oct 21 |
6 |
| 26 |
28856074 | Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. | 2017 Jun 29 |
2 |
| 27 |
28978004 | Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. | 2017 Sep 15 |
2 |
| 28 |
29070044 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. | 2017 Oct 25 |
2 |
| 29 |
29291017 | miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer. | 2017 Dec 5 |
2 |
| 30 |
27009458 | Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer. | 2016 Jan |
1 |
| 31 |
27491481 | Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. | 2016 Oct |
2 |
| 32 |
28118723 | [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects]. | 2016 Fall |
1 |
| 33 |
25695958 | Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas. | 2015 Apr |
1 |
| 34 |
26536870 | Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. | 2015 Nov |
1 |
| 35 |
26590813 | ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. | 2015 Dec |
3 |
| 36 |
24472707 | Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. | 2014 Jan 29 |
1 |
| 37 |
24663045 | Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. | 2014 Apr 20 |
1 |
| 38 |
24725461 | Articular cartilage chondrocytes express aromatase and use enzymes involved in estrogen metabolism. | 2014 Apr 11 |
2 |
| 39 |
25421542 | Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. | 2014 Nov 25 |
1 |
| 40 |
23704778 | Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. | 2013 Sep |
1 |
| 41 |
23980056 | The effect of letrozole with misoprostol for medical termination of pregnancy on the expression of steroid receptors in the placenta. | 2013 Nov |
3 |
| 42 |
24213953 | Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. | 2013 Nov 8 |
1 |
| 43 |
22550166 | AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. | 2012 Jun 15 |
4 |
| 44 |
22802308 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. | 2012 Aug 20 |
1 |
| 45 |
21245100 | Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. | 2011 Mar 1 |
2 |
| 46 |
21413907 | Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers? | 2011 May |
1 |
| 47 |
21555689 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. | 2011 Jun 10 |
1 |
| 48 |
21870129 | Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. | 2011 Dec |
4 |
| 49 |
21916582 | Autophagy and endocrine resistance in breast cancer. | 2011 Aug |
1 |
| 50 |
22006739 | Lapatinib in the treatment of HER-2 overexpressing breast cancer. | 2011 Jul-Sep |
2 |